Brazil Vaccine Market Summary 2025

Market Size in 2024: USD 1.7 Billion
Market Forecast in 2033: USD 2.8 Billion
Market Growth Rate 2025-2033: 6.0%

The Brazil vaccine market is projected to advance at a compound annual growth rate of 6.0% from 2025 to 2033. Valued at USD 1.7 billion in 2024, the market is expected to reach USD 2.8 billion by 2033. This robust expansion is driven by universal immunization program upgrades, rising demand for adult and travel vaccines, and continuous technology transfer that strengthens domestic biopharma capacity.

Brazil Vaccine Market Growth Drivers:

National Immunization Program Expansion

In January 2025, the Ministry of Health added RSV, meningococcal B and shingles to the SUS calendar, increasing annual doses by 14 million. Budget allocations rose BRL 1.9 billion, while states received cold-chain expansion grants that cover 1,800 new rural clinics. The broader schedule sustains predictable demand for both imported and domestically produced vaccines, supporting long-term procurement contracts and encouraging local fill-and-finish partnerships.

ANVISA Accelerated Pathway for mRNA Platforms

ANVISA introduced a 90-day rolling review in March 2025 for mRNA vaccines that demonstrate WHO emergency listing, cutting traditional approval time by half. The first applicant received clearance within 97 days, enabling a domestic booster campaign ahead of the Southern Hemisphere flu season. Faster regulatory timelines reduce market entry barriers for novel platform developers and signal Brazil’s alignment with global innovation cycles, encouraging technology transfer investments.

Bio-Manguinhos Technology Transfer Hub

Fiocruz announced in May 2025 that its Bio-Manguinhos institute will receive BRL 480 million to build a modular mRNA production suite with capacity for 120 million doses per year. Initial agreements with global innovators cover influenza and Covid-19 candidates, with future expansion into personalized cancer vaccines. Local production lowers cost per dose by an estimated 30%, strengthens pandemic preparedness and positions Brazil as a regional export hub for Latin American immunization programs.

Request a free sample copy of the Brazil Vaccine Market Report 2025-2033: https://www.imarcgroup.com/Brazil-vaccine-market/requestsample

Brazil Vaccine Market Segmentation:

Product Type Insights:

• Multivalent Vaccine
• Monovalent Vaccine

Treatment Type Insights:

• Preventive Vaccine
• Therapeutic Vaccine

Technology Insights:

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others

Route of Administration Insights:

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others

Patient Type Insights:

• Pediatric
• Adult

Indication Insights:

• Bacterial Diseases
  • Meningococcal Disease
  • Pneumococcal Disease
  • Diphtheria/Tetanus/Pertussis (DPT)
  • Tuberculosis
  • Haemophilus Influenzae (Hib)
  • Typhoid
  • Others
• Viral Diseases
  • Hepatitis
  • Influenza
  • Human Papillomavirus (HPV)
  • Measles/Mumps/Rubella (MMR)
  • Rotavirus
  • Herpes Zoster
  • Varicella
  • Japanese Encephalitis
  • Rubella
  • Polio
  • Rabies
  • Dengue
  • Others

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Institutional Sales
• Others

End User Insights:

• Hospitals
• Clinics
• Vaccination Centers
• Academic and Research Institutes
• Others

Regional Insights:

• Southeast
• South
• Northeast
• North
• Central-West

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Request Customization: https://www.imarcgroup.com/request?type=report&id=16925&flag=E

Brazil Vaccine Market News:

• In April 2025, Butantan Institute shipped 8 million quadrivalent influenza doses to Argentina under a regional solidarity pact.
• The Central Bank approved in May 2025 a BRL 220 million low-interest credit line for SMEs developing thermostable formulations.
• A national HPV vaccination catch-up campaign launched in June 2025 targets 3.7 million adolescents and is expected to reduce cervical cancer incidence by 70%.
• São Paulo state government signed a public-private agreement in July 2025 to establish a fill-and-finish facility dedicated to dengue vaccines, with production slated for 2027.

Key highlights of the Report:

• 
  
  • Market Performance (2019-2024)
  • Market Outlook (2025-2033)
  • COVID-19 Impact on the Market
  • Porter’s Five Forces Analysis
  • Strategic Recommendations
  • Historical, Current and Future Market Trends
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Structure of the Market
  • Value Chain Analysis
  • Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.